Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi; Ohtsu, Hiroshi; Ota, Yasunori; Shibahara, Junji; Tanaka, Minoru published the artcile< Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial>, Application of C19H34O2, the main research area is intratumoral oncolytic herpes virus recurrent glioblastoma.
This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47Δ, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clin. Trial Registry UMIN000015995). G47Δ was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47Δ initiation was 84.2% (95% confidence interval, 60.4-96.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8-23.6) months after G47Δ initiation and 28.8 (20.1-37.5) months from the initial surgery. The most common G47Δ-related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47Δ administration, which was characteristic to this therapy. Thus, the best overall response in 2 yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4+/CD8+ lymphocytes and persistent low numbers of Foxp3+ cells. This study showed a survival benefit and good safety profile, which led to the approval of G47Δ as the first oncolytic virus product in Japan.
Nature Medicine (New York, NY, United States) published new progress about Adult, mammalian. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application of C19H34O2.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics